Image Source: Unsplash
 

The 5 constituents in the munKNEE Psychedelic Drug Stocks Index are DOWN 29.2%, on average, so far in 2023 and are now DOWN 85.9% from their highs in 2021. Below is how each constituent stock has performed so far in December, in descending order and YTD:

1. Compass Pathways (CMPS): UP 48.0% MTD; UP 10.2% YTD
   • is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
2. Atai Life Sciences (ATAI): UP 29.8% MTD; DOWN 49.2% YTD
   • is focused on the use of ketamine, DMT and ibogaine.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
3. Mind Medicine (MNMD): UP 17.3% MTD; UP 75.9% YTD
   • is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
4. GH Research (GHRS): DOWN 11.9% MTD; DOWN 43.4% YTD
   • is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
5. Incannex Healthcare (IXHL): DOWN 47.3% MTD; DOWN 61.6% YTD
   • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.

Summary

The munKNEE Psychedelic Drug Stocks Index is UP 9.1% MTD but is still DOWN 29.2% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, is UP 9.2% MTD but is "only" DOWN 22.4% YTD.

More By This Author:

American Cannabis MSO Stocks Index Has Rebounded In 2023
An Atrocious Year For Canadian Cannabis LP Stocks Index: Down 64% YTD
What's Cloud Computing? How Have The Top 8 Companies Done YTD?